Joshua Meyers
About Joshua Meyers
Joshua Meyers is a Senior AI Scientist at BenevolentAI in the United Kingdom, with expertise in chemoinformatics and artificial intelligence.
Current Role at BenevolentAI
Joshua Meyers currently holds the position of Senior AI Scientist at BenevolentAI in the United Kingdom. In this role, he applies his expertise in artificial intelligence to advance the company's AI-driven drug discovery projects. Joshua's work focuses on leveraging AI technologies to uncover new therapeutic opportunities and improve the drug development process.
Previous Roles at BenevolentAI
Before becoming a Senior AI Scientist at BenevolentAI, Joshua Meyers worked as a Senior Chemoinformatics Data Scientist from 2019 to 2020, and prior to that, as a Chemoinformatics Data Scientist from 2017 to 2019. These roles, both based in London, involved utilizing chemoinformatics to support drug discovery and development efforts. His transition within the company highlights his growing expertise and pivot to AI-driven initiatives.
Educational Background
Joshua Meyers earned his Doctor of Philosophy (PhD) in Chemoinformatics from The Institute of Cancer Research, University of London, studying from 2013 to 2017. He also holds an integrated Master of Chemistry (MChem) degree with a year in industry from the University of Leeds, completed between 2009 and 2013. His academic training provided a solid foundation in both chemoinformatics and chemistry, preparing him for his career in computational science and AI.
Experience at AstraZeneca
During the 2011 to 2012 period, Joshua Meyers worked at AstraZeneca as a Computational Chemist during his placement year. Based in Alderley Park, Cheshire, this role marked the beginning of his professional journey into computational chemistry. This experience allowed him to gain practical knowledge and skills that would later be instrumental in his work at BenevolentAI.
Transition to AI and Chemoinformatics Expertise
Joshua Meyers has successfully bridged the gap between the fields of chemoinformatics and artificial intelligence. His career began in chemoinformatics, where he utilized computational methods for drug discovery. Over time, he transitioned to AI applications within BenevolentAI. This dual expertise allows him to contribute uniquely to AI-driven drug discovery projects, combining deep knowledge of chemical data with cutting-edge AI technologies.